Cargando…

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature

PURPOSE: Post-neurosurgical infection caused by extensively drug resistant Pseudomonas aeruginosa (XDR-PA) are becoming a matter of great concern due to limited therapeutic options. Although not approved for these indications, the new BetaLactam-BetaLactamase Inhibitor combinations (BLBLIs) could re...

Descripción completa

Detalles Bibliográficos
Autores principales: Meschiari, Marianna, Franconi, Iacopo, Bacca, Erica, Bianco, Vincenzo, Orlando, Gabriella, Cuomo, Gianluca, Bedini, Andrea, Mussini, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569357/
https://www.ncbi.nlm.nih.gov/pubmed/33074365
http://dx.doi.org/10.1007/s15010-020-01539-9
_version_ 1783596713748987904
author Meschiari, Marianna
Franconi, Iacopo
Bacca, Erica
Bianco, Vincenzo
Orlando, Gabriella
Cuomo, Gianluca
Bedini, Andrea
Mussini, Cristina
author_facet Meschiari, Marianna
Franconi, Iacopo
Bacca, Erica
Bianco, Vincenzo
Orlando, Gabriella
Cuomo, Gianluca
Bedini, Andrea
Mussini, Cristina
author_sort Meschiari, Marianna
collection PubMed
description PURPOSE: Post-neurosurgical infection caused by extensively drug resistant Pseudomonas aeruginosa (XDR-PA) are becoming a matter of great concern due to limited therapeutic options. Although not approved for these indications, the new BetaLactam-BetaLactamase Inhibitor combinations (BLBLIs) could represent a valid salvage treatment. We describe one nosocomial meningitis and two cervical osteomyelitis due to an XDR-PA who were treated with ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) and review the literature. METHODS: The first and the third patients developed an osteomyelitis following cervical stabilization surgery due to an XDR-PA. Although the first patient started treatment with a high dose of C/T, resistance to C/T occurred, so therapy was switched to CZA plus aztreonam. The third patient switched to aztreonam plus CZA due to development of acute kidney injury during therapy with colistin. The second patient had an XDR-PA meningitis following the insertion of an external ventricular catheter and he was treated with C/T plus meropenem and amikacin. RESULTS: All three cases reported were successfully conservatively treated thanks to the use of the new BLBLIs with different combinations. Only few experiences demonstrated an equally favorable outcome: one patient treated with C/T plus fosfomycin for otogenic meningitis caused by an XDR-PA and another case of XDR-PA post-surgical meningitis with CZA in combination with colistin. Finally, the combination of CZA plus aztreonam has proven to be effective on XDR-PA only in limited mostly in vitro studies. CONCLUSION: These recently developed antibiotics, C/T and CZA are promising and complementary therapy options against post-neurosurgical hard-to-treat P. aeruginosa infections. Further prospective real-life studies are required to validate these findings in this special setting.
format Online
Article
Text
id pubmed-7569357
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75693572020-10-19 Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature Meschiari, Marianna Franconi, Iacopo Bacca, Erica Bianco, Vincenzo Orlando, Gabriella Cuomo, Gianluca Bedini, Andrea Mussini, Cristina Infection Case Report PURPOSE: Post-neurosurgical infection caused by extensively drug resistant Pseudomonas aeruginosa (XDR-PA) are becoming a matter of great concern due to limited therapeutic options. Although not approved for these indications, the new BetaLactam-BetaLactamase Inhibitor combinations (BLBLIs) could represent a valid salvage treatment. We describe one nosocomial meningitis and two cervical osteomyelitis due to an XDR-PA who were treated with ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) and review the literature. METHODS: The first and the third patients developed an osteomyelitis following cervical stabilization surgery due to an XDR-PA. Although the first patient started treatment with a high dose of C/T, resistance to C/T occurred, so therapy was switched to CZA plus aztreonam. The third patient switched to aztreonam plus CZA due to development of acute kidney injury during therapy with colistin. The second patient had an XDR-PA meningitis following the insertion of an external ventricular catheter and he was treated with C/T plus meropenem and amikacin. RESULTS: All three cases reported were successfully conservatively treated thanks to the use of the new BLBLIs with different combinations. Only few experiences demonstrated an equally favorable outcome: one patient treated with C/T plus fosfomycin for otogenic meningitis caused by an XDR-PA and another case of XDR-PA post-surgical meningitis with CZA in combination with colistin. Finally, the combination of CZA plus aztreonam has proven to be effective on XDR-PA only in limited mostly in vitro studies. CONCLUSION: These recently developed antibiotics, C/T and CZA are promising and complementary therapy options against post-neurosurgical hard-to-treat P. aeruginosa infections. Further prospective real-life studies are required to validate these findings in this special setting. Springer Berlin Heidelberg 2020-10-19 2021 /pmc/articles/PMC7569357/ /pubmed/33074365 http://dx.doi.org/10.1007/s15010-020-01539-9 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Meschiari, Marianna
Franconi, Iacopo
Bacca, Erica
Bianco, Vincenzo
Orlando, Gabriella
Cuomo, Gianluca
Bedini, Andrea
Mussini, Cristina
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title_full Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title_fullStr Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title_full_unstemmed Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title_short Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
title_sort ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569357/
https://www.ncbi.nlm.nih.gov/pubmed/33074365
http://dx.doi.org/10.1007/s15010-020-01539-9
work_keys_str_mv AT meschiarimarianna ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT franconiiacopo ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT baccaerica ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT biancovincenzo ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT orlandogabriella ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT cuomogianluca ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT bediniandrea ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature
AT mussinicristina ceftazidimeavibactamandceftolozanetazobactamforthetreatmentofextensivelydrugresistantpseudomonasaeruginosapostneurosurgicalinfectionsthreecasesandareviewoftheliterature